TIMIPERONE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H24FN3OS.ClH
Molecular Weight	433.97
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)N3C(=S)NC4=C3C=CC=C4

InChI

InChIKey=VUGXUHIAJYYOSP-UHFFFAOYSA-N

InChI=1S/C22H24FN3OS.ClH/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28;/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28);1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C22H24FN3OS
Molecular Weight	397.509
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10215017
Curator's Comment: description was created based on several sources, including: https://medical.mt-pharma.co.jp/di/file/dc/tol_f.htm https://www.medicallibrary-dsc.info/di/tolopelon_tablets_3mg/pdf/if_tp_tab_1301_09.pdf

Timiperone is a neuroleptic agent that was developed in Japan. Timiperone has a potent antipsychotic activity, which is comparable to other butyrophenones such as haloperidol (HAL). Timiperone has a five-eight-times higher affinity to dopamine receptors and a 15-times higher affinity to serotonin receptors than those of HAL. Clinical trials have suggested that TIM has a specific action against negative symptoms such as lack of initiative or blunted affect as well as positive symptoms such as delusions and hallucinations in schizophrenics.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: http://www.ncbi.nlm.nih.gov/pubmed/43256 \| http://link.springer.com/referenceworkentry/10.1007%2F978-3-540-68706-1_1902 \| http://www.genome.jp/dbget-bin/www_bget?D02035	Antagonist 2778
serotonin receptor signaling pathway 6 Target ID: GO:0007210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/43256 \| http://www.ncbi.nlm.nih.gov/pubmed/10215017	Modulator 828

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 298 Sources: http://www.kegg.jp/medicus-bin/japic_med_product?id=00048858	Primary		Approved 8429	Tolopelon Approved Use Timiperone is efficient against schizophrenia. Launch Date 1983

PubMed

Title	Date	PubMed
Effect of hyperprolactinemia induced by pituitary grafts or castration on porphyrin content of the mouse Harderian gland.	2001 Aug	11552298
Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.	2004 Nov 26	15519367

Patents

Sample Use Guides

In Vivo Use Guide

Dosage gradually increase from 0,5-3 mg to 3-12 mg daily during 12 weeks

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:52:39 GMT 2023` Edited by `admin` on `Fri Dec 15 16:52:39 GMT 2023`
Record UNII	605T96VHKF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TIMIPERONE HYDROCHLORIDE

Common Name

English

1-BUTANONE, 4-(4-(2,3-DIHYDRO-2-THIOXO-1H-BENZIMIDAZOL-1-YL)-1-PIPERIDINYL)-1-(4-FLUOROPHENYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

Code System Code Type Description

CAS

65053-29-4

Created by admin on Fri Dec 15 16:52:39 GMT 2023 , Edited by admin on Fri Dec 15 16:52:39 GMT 2023

NON-SPECIFIC STOICHIOMETRY

CAS

62621-49-2

Created by admin on Fri Dec 15 16:52:39 GMT 2023 , Edited by admin on Fri Dec 15 16:52:39 GMT 2023

PRIMARY

PUBCHEM

15571090

Created by admin on Fri Dec 15 16:52:39 GMT 2023 , Edited by admin on Fri Dec 15 16:52:39 GMT 2023

PRIMARY

FDA UNII

605T96VHKF

Created by admin on Fri Dec 15 16:52:39 GMT 2023 , Edited by admin on Fri Dec 15 16:52:39 GMT 2023

PRIMARY

Related Record Type Details


					626DQ7N19L

TIMIPERONE

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/10215017Curator's Comment: description was created based on several sources, including: https://medical.mt-pharma.co.jp/di/file/dc/tol_f.htm https://www.medicallibrary-dsc.info/di/tolopelon_tablets_3mg/pdf/if_tp_tab_1301_09.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10215017
Curator's Comment: description was created based on several sources, including: https://medical.mt-pharma.co.jp/di/file/dc/tol_f.htm https://www.medicallibrary-dsc.info/di/tolopelon_tablets_3mg/pdf/if_tp_tab_1301_09.pdf